Seaport Therapeutics, Inc.
SPTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002042347
In the last 90 days, Seaport Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 54 institutions reported holding it in 13F filings for Q2 2026, worth $815.3M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $1.18B
- Insider buysLast 90 days, $99.3K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +54 vs. previous quarter
- 54
- 13F valueReported value at the end of Q2 2026
- $815.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 3.73M
- Shares sold short
- Change
- +14.5K
- +0.4% vs. previous
- Days to cover
- 17.42
- At average daily volume
Superinvestors holding SPTX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding SPTX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Seaport Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 4, 2026 (view filing)7:30 AM ET | Nov 3 | 1 day | Torres DeniceDirector | PPurchase | +5.00K | $19.87 | +$99.3K | New position5.00K after | |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Hombach Robert J.Director | PPurchase | +13.0K | $18.14 | +$235.8K | New position13.0K after | |
| May 4, 2026 (view filing)6:02 PM ET | May 4 | Same day | Crandell Keith and 6 others10% Owner | PPurchase | +1.10M | $18.00 | +$19.8M | +21.2%6.29M after |
Top 10 13F holders, Q2 2026
See all 54 holdersThe largest institutional positions in Seaport Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 6,294,951 | $136.6M | 12.42% | +6,294,951 | New |
| General Atlantic LLC | 6,101,582 | $132.5M | 4.56% | +6,101,582 | New |
| Sofinnova Investments, Inc. | 3,564,871 | $77.4M | 4.14% | +3,564,871 | New |
| Goldman Sachs Group Inc | 2,178,642 | $47.3M | 0.00% | +2,178,642 | New |
| TRV GP VI, LLC | 2,061,222 | $44.8M | 19.27% | +2,061,222 | New |
| Canada Pension Plan Investment Board | 1,975,791 | $42.9M | 0.02% | +1,975,791 | New |
| JPMorgan Chase & Co | 1,815,845 | $40.9M | 0.00% | +1,815,845 | New |
| Foresite Capital Management VI LLC | 1,779,521 | $38.7M | 6.02% | +1,779,521 | New |
| Price T Rowe Associates Inc | 1,308,604 | $28.4M | 0.00% | +1,308,604 | New |
| FMR LLC | 1,185,100 | $25.7M | 0.00% | +1,185,100 | New |
Holders of 5% or more of SPTX
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Seaport Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| PureTech LYT, Inc. | 13G | 31.20%16.7M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| ARCH Venture Fund XII, L.P. | 13D | 11.90%6.29M shares | New | May 6, 20261 filing | May 6, 2026 | SEC |
| General Atlantic LLC | 13D | 11.50%6.10M shares | New | May 11, 20261 filing | May 11, 2026 | SEC |
| Zohar Daphne | 13G | 9.10%5.23M shares | New | Aug 5, 20261 filing | Aug 5, 2026 | SEC |
| Paul Steven M | 13G | 6.30%3.52M shares | New | Aug 5, 20261 filing | Aug 5, 2026 | SEC |